The allotment for the highly awaited ₹3,280 crore IPO of Anthem Biosciences was finalized on July 17, 2025, after witnessing overwhelming demand from investors across all categories. Subscribers can now check their allotment status on the official websites of BSE India or the registrar, Link Intime India Pvt Ltd.
The IPO, priced between ₹445 and ₹480 per share, was oversubscribed nearly 48 times. Institutional interest drove much of the demand—Qualified Institutional Buyers (QIBs) bid 117 times their reserved portion, Non-Institutional Investors (NIIs) 54 times, and Retail Investors almost 15 times, according to The Economic Times.
Successful applicants will receive share credits in their demat accounts by July 18, while refunds to unallocated investors will also be initiated on the same day.
Grey Market Premium Reflects Bullish Sentiment
As anticipation builds ahead of the listing, the Grey Market Premium (GMP) for Anthem Biosciences remains robust, hovering between ₹180 and ₹200. This translates to an expected listing gain of 37%–42% over the IPO’s upper price band, as reported by Business Standard.
Analysts attribute the strong GMP to the company’s solid business fundamentals and leadership in the Contract Research and Manufacturing Services (CRAMS) space. Anthem Biosciences’ diversified portfolio across pharmaceuticals, biotechnology, and biosimilars, along with steady financial performance, has helped boost investor confidence.
Additionally, the company’s expansion strategy and upcoming R&D investments have further reinforced optimism among institutional players and retail investors alike.
Listing Day Outlook: Strong Debut Anticipated
Anthem Biosciences will make its stock market debut on July 19, 2025, on both BSE and NSE. Investors can confirm allotment details using their PAN, application number, or demat ID via either the BSE website or Link Intime’s portal, as noted by CNBCTV18.
Market experts predict a strong opening driven by solid fundamentals and investor enthusiasm. Given the significant oversubscription, high GMP, and sector growth potential, the IPO is being viewed as one of the most promising listings of 2025.
If the momentum holds, Anthem Biosciences could join the ranks of top-performing pharma stocks post-listing—marking a successful entry into the public markets and validating investor confidence in India’s booming life sciences sector.
